Browse by author
Lookup NU author(s): Professor Alan Boddy,
Professor Herbie Newell,
Professor Alan Calvert
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Purpose: A phase I, multicenter trial of the thymidylate synthase (TS) inhibitor THYMITAQ (nolatrexed dihydrochloride; Agouron Pharmaceuticals, Inc, San Diego, CA) given 5-day continuous infusion was performed to establish the maximum-tolerated dose (MTD) and to investigate pharmacokinetics, pharmacodynamics, and antitumor effects. Methods: In vitro and in viva preclinical studies demonstrated increased activity with prolonged nolatrexed exposure. In 32 patients, nolatrexed was given as a 5-day infusion at 96 to 1,040 mg/m2/d for 5 days. Pharmacokinetics were determined from high- performance liquid chromatography (HPLC) analyses of plasma and urine. In addition to studying toxicity, plasma deoxyuridine (UdR) elevations were measured as a marker of TS inhibition. Results: The MTD was 904 mg/m2/d for 5 days and the recommended phase II dose is 800 mg/m2/d for 5 days. The dose-limiting toxicity was neutropenia with clinically significant thrombocytopenia and mucositis. These antiproliferative toxicities of nolatrexed were predictable and reversible. A partial response that lasted 3 months occurred in a patient with metastatic colarectal cancer. Pharmacokinetics were nonlinear, with the median plasma clearance (CI) decreasing from 151 mL/min/m2 (range, 124 to 211) at 96 mg/m2/d for 5 days to 49 mL/min/m2 (range, 30 to 84) at 768 mg/m2/d for 5 days. The half-life (t 1/4 ) was 173 minutes (range, 43 to 784) and 18% (range, 9% to 35%) of the dose was excreted unchanged in the urine. Plasma UdR increased, but returned to pretreatment levels after the end of infusion. Hematologic toxicity was significantly related to nolatrexed plasma concentrations and dose. Conclusion: Nolatrexed can be safely administered to patients at o dose of 800 mg/m2/d over 5 days continuous intravenous infusion and this schedule is associated with antitumor effects. The phase II evaluation of nolatrexed is ongoing.
Author(s): Rafi, I., Boddy, A. V., Calvete, J., Taylor, G. A., Newell, D. R., Bailey, N. P., Lind, M., Green, M., Hines, J., Johnstone, A., Clendeninn, N., Calvert, A. H.
Publication type: Article
Publication status: Published
Journal: Journal of Clinical Oncology
Print publication date: 01/03/1998
ISSN (print): 0732-183X
PubMed id: 9508200